Skip to search formSkip to main contentSkip to account menu

AZD6140

Known as: AZD 6140, AZD-6140 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Ticagrelor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Evaluation of comparative treatment effects using indirect comparisons.
Review
2012
Review
2012
Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm?
The PLATO trial was a phase 3, randomized, double-blind, parallel-group, multinational, clinical study comparing the efficacy of… 
2011
2011
Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y12 antagonist ticagrelor
Summary Platelet P2Y12 receptors play an important role in arterial thrombosis by stimulating thrombus growth. Both irreversibly… 
2009
2009
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial
AZD6140, the first reversible oral P2Y12 receptor antagonist, exhibits greater and more consistent inhibition of platelet… 
2009
2009
Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment
BackgroundMild hypothermia is currently standard of care for cardiac arrest patients in many hospitals and a common belief is… 
2008
2008
Carba‐nucleosides as Potent Antagonists of the Adenosine 5′‐Diphosphate (ADP) Purinergic Receptor (P2Y12) on Human Platelets
Whereas the activation and aggregation of blood platelets are crucial to normal hemostasis, this ensemble is also a key factor in… 
2007
2007
Abstract 245: AZD6140 Inhibits Adenosine Uptake Into Erythrocytes and Enhances Coronary Blood Flow After Local Ischemia or Intracoronary Adenosine Infusion
Background. Adenosine is one of the mediators of the reactive hyperemia response to temporary coronary artery occlusion. AZD6140… 
2007
2007
New developments in oral antiplatelet therapy
Oral antiplatelet therapy is central to the treatment of patients with thrombotic diseases. Yet, despite the proven efficacy of… 
Review
2007
Review
2007
AZD6140
Oral antiplatelet therapy with P2Y12 receptor blockers (especially clopidogrel) is the current choice of treatment during acute… 
2006
2006
Dyspnoea after AZD6140: safety first?
Husted et al. 1 published dose-finding Phase 2 randomized study comparing novel oral reversible platelet P2Y12 antagonist… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)